论文部分内容阅读
自1980年 Rotmensch 等首次描述乙胺碘呋酮(AMI)与肺纤维化可能有关以来,各家报道 AMI 致肺炎的发生率差异甚大(0.5～17.6%)。其中部分可能由于缺乏明确的诊断标准。本文旨在根据特异性的临床诊断标准来确定 AMI 肺毒性的发生率,并前瞻评价肺功能试验在肺毒性的诊断和危险因素预测中
Since Rotmensch et al first described in 1980 that amiodarone (AMI) may be associated with pulmonary fibrosis, the incidence of pneumonia caused by AMI varies widely (0.5-17.6%). Some may be due to the lack of a clear diagnostic criteria. This article aims to determine the incidence of AMI pulmonary toxicity based on specific clinical diagnostic criteria and to prospectively evaluate the role of pulmonary function tests in the prediction of pulmonary toxicity and risk factors